# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Alan Turing (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML007-SYN-TD
- Date: 1953-04-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rupert Hallam, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- Breasts enlarged and tender after a year of estrogen injections he was made to accept; finds it humiliating and has stopped changing in front of other runners **S**
- Low mood, poor sleep, low libido, and loss of interest since the prosecution and the hormone course; wants to know whether his body will return to normal, and wants no treatment he has not agreed to **S**

## Your goals

- Testosterone, LH, and FSH back in the reference range within six months of the last estrogen dose, without testosterone therapy. Target: 1953-08-04. Recorded outcome: Testosterone 452 ng/dL with normal LH and FSH at sixteen weeks. **S**
- Breast tenderness gone and gynecomastia reduced; a surgical opinion offered if it persists and troubles him. Target: 1953-10-06. Recorded outcome: Tenderness gone by six months; small residual glandular tissue; watchful waiting to twelve months. **S**
- Depression response (PHQ-9 down by at least 50 percent) by sixteen weeks, then remission (PHQ-9 below 5). Target: 1953-10-06. Recorded outcome: PHQ-9 7 at sixteen weeks (down 53 percent) and 4 at six months. **S**
- Back to running about 40 km a week and changing at his club again. Target: 1953-10-06. Recorded outcome: Running 40 km a week and back with the club by six months. **S**

## What we agreed to do

- Consent first: every examination, test, and treatment is explained and offered, and he may decline any of it; intimate examinations only with his agreement at each step and with a chaperone offered. The estrogen he was given as a condition of avoiding prison was not freely consented treatment, and no further doses will be given. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018); APA Guidelines for Psychological Practice With Sexual Minority Persons (2021) **S**
- Gynecomastia workup: breast and testicular examination; testosterone, estradiol, LH, FSH, prolactin, SHBG, hCG, AFP, liver, kidney, and thyroid tests today; scrotal ultrasound; breast ultrasound only if the examination becomes equivocal. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018) **S**
- Endocrinology consultation to confirm that the estrogen explains the findings and to advise on recovery of the gonadal axis, testosterone therapy, bone health, and surgery. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018) **S**
- Watchful waiting for the gynecomastia after the estrogen stops; testosterone, estradiol, LH, and FSH every six to eight weeks until normal; no testosterone therapy while the axis is recovering; a surgical opinion if gynecomastia persists about twelve months and troubles him. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018) **S**
- Bone health: vitamin D replacement, calcium from food, continued running and strength work; bone density scan only if hypogonadism persists beyond six months or a fracture occurs. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018); Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline (2012) **S**
- Weekly psychotherapy with a gay-affirming clinic psychologist for about 16 sessions, addressing the prosecution, the coerced treatment, and minority stress; an antidepressant offered and declined for now, to be reconsidered if the PHQ-9 has not fallen by half at about eight weeks. Guideline: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); APA Guidelines for Psychological Practice With Sexual Minority Persons (2021) **S**
- Collaborative safety plan with warning signs, coping steps, people to contact, the clinic number, and the 988 Suicide & Crisis Lifeline; suicide-risk review and PHQ-9 at every visit. Guideline: VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
- Sexual health as routine adult care: HIV and STI testing and a PrEP discussion offered at his preventive visit, with his consent; libido and erectile function reviewed as testosterone recovers. Guideline: APA Guidelines for Psychological Practice With Sexual Minority Persons (2021); Sexually Transmitted Infections Treatment Guidelines: Men Who Have Sex with Men (2021); Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis (2023) **S**
- Affirming practice: his orientation, name, and pronouns recorded as he chooses; his records shared only with his consent; a written letter from this clinic, at his request, confirming that the estrogen he was given was not medically indicated. Guideline: APA Guidelines for Psychological Practice With Sexual Minority Persons (2021) **S**
- Add bupropion XL 150 mg each morning, chosen by him after an informed discussion of options and side effects; nurse telephone check at two weeks; PHQ-9 and blood pressure at each visit. Guideline: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**

## Follow-up

- 1953-04-14: New-patient primary care visit for breast enlargement, low libido, and low mood after a year of high-dose estrogen given without his consent **S**
- 1953-04-28: Two-week follow-up with endocrinology consultation and scrotal ultrasound **S**
- 1953-06-09: Eight-week review of hormone recovery and depression treatment **S**
- 1953-08-04: Sixteen-week review of hormone recovery and depression treatment **S**
- 1953-10-06: Six-month review of gynecomastia and depression in continuation treatment **S**
- 1953-10-20: Periodic adult preventive visit **S**

This teaching document does not replace care from a qualified clinician.
